{"id":"W4410809409","doi":"10.1200/jco.2025.43.16_suppl.6506","title":"Ziftomenib in relapsed/refractory (R/R) <i>NPM1</i> -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; NPM1; Refractory (planetary science); Oncology; Internal medicine; Mutant; Myeloid; Cancer research; Gene; Genetics; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001535711,0.0005650653,0.000794652,0.0003570093,0.0001704429,0.0007266949,0.0004395545,0.0004802256,0.00250999],"category_scores_gemma":[0.001045136,0.0002419464,0.000826299,0.0004854084,0.0002922949,0.0005054149,0.0002618276,0.001500348,0.0004476315],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008045159,"about_ca_system_score_gemma":0.0007046417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006348853,"about_ca_topic_score_gemma":0.00280157,"domain_scores_codex":[0.999589,0.000159846,0.00002545675,0.00006477342,0.00008301816,0.00007778238],"domain_scores_gemma":[0.9994729,0.0001149048,0.0002036159,0.00002967903,0.00003409283,0.0001447674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5620429,0.01709756,0.0874274,0.00280829,0.005135753,0.0006642549,0.0003306442,0.006094822,0.05844364,0.000937494,0.02395296,0.2350643],"study_design_scores_gemma":[0.4731705,0.2246668,0.2381042,0.0003548277,0.006513829,0.002428458,0.0002210997,0.006560127,0.01542293,0.001084343,0.03136653,0.0001063581],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805361,0.009078884,0.0006701805,0.0005626281,0.00008792595,0.001136743,0.004717881,0.00007152508,0.003138126],"genre_scores_gemma":[0.9841287,0.004139475,0.0009886896,0.0005732124,0.0001169788,0.0006115032,0.008096757,0.0000268464,0.001317785],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00250999,"threshold_uncertainty_score":0.008396745,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08539747359179765,"score_gpt":0.4797452026748207,"score_spread":0.394347729083023,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}